The CaSR gene is located in the 3q13.3-21 of the human genome (Janicic et al., 1995) and is composed of 8 exons; of those, two alternative exons, 1A and 1B, are located within the 5′-untranslated region (5′UTR) and are transcribed from two distinct promoters. Both 1A and 1B splice to exons 2–7 that translate the whole protein, which is comprised of 1,078 amino acids (Garrett et al., 1995; Chikatsu et al., 2000; Hendy and Canaff, 2016b).

Similar to the other receptors of the family C of GPCRs (i.e., metabotropic glutamate receptors (mGluRs), γ-aminobutyric acid_B (GABA_B) receptors, and some taste receptors), the CaSR is comprised of a large extracellular domain (ECD) with a bilobed structure, termed Venus Flytrap domain (VFT), deputed to ligand binding. The CaSR anchors to the plasma membrane with a 7 α-helices transmembrane domain (7TM), which is connected to the ECD through a cysteine reach domain. With its intracellular C-terminal domain, the CaSR is able to interact with the heterotrimeric G proteins and with β-arrestin, thereby activating diversified signaling cascades. By binding α_i/o, α_q/11 and α_12/13, the CaSR is able to inhibit adenylate cyclase and cAMP synthesis, activate the MAPK cascade through extracellular-signal regulated kinase (ERK) phosphorylation, promote intracellular calcium release by activating the phospholipase C (PLC)-inositol 1,4,5-triphosphate (IP₃) cascade, and induce membrane ruffling. Furthermore, the CaSR, by binding β-arrestin, is able to modulate its own endocytosis and ERK phosphorylation (Hofer and Brown, 2001; Hofer and Brown, 2003; Brauner-Osborne et al., 2006; Brennan et al., 2013; Conigrave and Ward, 2013; Hannan et al., 2018).

The CaSR was first identified in the parathyroid glands as a “calcium-sensing” receptor (Brown et al., 1993); however, later studies reported it to be sensitive also to other ions, such as Mg²⁺ and Gd³⁺, and to a plethora of other molecules that stimulate its activity, including aminoglycoside antibiotics (e.g., neomycin), polypeptides (i.e., poly-l-arginine, poly-l-lysine and amyloid β peptides), polyamines (i.e., spermine, spermidine and putrescine), glutamyl dipeptides, and some amino acids, such as phenylalanine and tryptophan (Hofer and Brown, 2003; Tennakoon et al., 2016; Iamartino et al., 2018). The broad diffusion and variety of these molecules allow systemic activation of the CaSR in different tissues, conferring a multiplicity of cellular responses.

The best described physiological role of the CaSR is its capability to control serum calcium balance [please see the following refs (Hofer and Brown, 2001; Brennan et al., 2013; Hannan et al., 2018)]. The importance of the CaSR for calcium homeostasis is the fact that CaSR mutations are associated with inherited diseases characterized by calcium and PTH disbalance. Hypercalcemic diseases can derive from loss-of-function CaSR mutations, such as type 1 familial hypocalciuric hypercalcemia (FHH1) and neonatal severe hyperparathyroidism (NSHPT) (Chattopadhyay and Brown, 2006; Hannan et al., 2012; Hannan and Thakker, 2013; Hannan et al., 2016), while gain-of-function CaSR mutations are associated with hypocalcemic disorders, such as type 1 autosomal dominant hypocalcemia (ADH1) and type 5 Bartter syndrome (Vargas-Poussou et al., 2002; Chattopadhyay and Brown, 2006; Hannan and Thakker, 2013; Hannan et al., 2016; Hannan et al., 2018).

The impairment of CaSR expression/functionality is the main culprit of primary and secondary hyperparathyroidism. The former is caused by the development of hyperplasia or adenoma of generally one of the four parathyroid glands, while the latter results as a complication of chronic kidney disease (CKD), where hyperphosphatemia, caused by kidney failure, induces the aberrant enlargement of the parathyroid glands. In both conditions, the hyperplastic parathyroid glands fail to regulate serum Ca²⁺ homeostasis, leading to the increase of PTH secretion. While primary hyperparathyroidism tends to be asymptomatic, the late-stages of secondary hyperparathyroidism are characterized by concomitant hyperphosphatemia and hypercalcemia that are associated to life-threatening vascular calcifications (Fraser, 2009; Cunningham et al., 2011; Naveh-Many and Volovelsky, 2020). While primary hyperparathyroidism is mostly treated surgically, secondary hyperparathyroidism can be treated pharmacologically, in particular by stimulating the CaSR either through the FDA-approved cinacalcet, a synthetic positive allosteric CaSR modulator, or with the newly clinically approved etelcalcetide, a recently developed synthetic CaSR agonist (Nemeth et al., 2004; Fraser, 2009; Cunningham et al., 2011; Hamano et al., 2017).

In addition to its “calcitropic” functions, the CaSR plays other physiological roles in the body, comprehensively reviewed by S. Brennan et al. and Hannan et al. (2018) (Brennan et al., 2013). Moreover, the CaSR has been found to be a multifunctional factor in cancer, as reviewed in detail by Tennakoon et al. (2016).

Because calcium plays pivotal roles in inflammation, its receptor, the CaSR, is an important mediator of the inflammatory processes. Compelling evidence has demonstrated that the CaSR mediates inflammation in various tissues and immune cells (Figure 1), where it mediates their activity and chemokinesis.

One of the first evidences of a calcium-sensing mechanism inside immune cells that regulates their activity and cytokine production came from a study by Bornefalk et al. (1997), who found that extracellular calcium promoted both in vitro and in vivo the release of IL-6 from mononuclear blood cells. In the same year, the CaSR was found to be expressed in the hematopoietic precursor cells, in particular in mononuclear cells isolated from whole human and mouse bone marrow tissues (House et al., 1997). Afterwards, Yamaguchi et al. (1998) demonstrated that CaSR was indeed expressed in human peripheral blood monocytes. In monocytes, the CaSR was found to be functional and modulable, being able to mediate cell chemotaxis induced by extracellular calcium (Olszak et al., 2000). Two independent studies found that calcium was able to trigger IL-1β secretion from monocytes via the activation of the NLRP3 inflammasome, and demonstrated that this activation was dependent on CaSR expression and activity (Lee et al., 2012; Rossol et al., 2012). Following studies corroborated those findings, observing that the CaSR is able to trigger a pro-inflammatory response by activating the NLRP3 inflammasome in monocytes and differentiated macrophages (Liu et al., 2015; Jäger et al., 2020; Su et al., 2020) and to mediate constitutive micropinocytosis, thus contributing to antigen engulfment and subsequent antigen presentation (Canton et al., 2016).

Additionally, the CaSR was found to be expressed in other immune cells. In peripheral blood polymorphonuclear neutrophils, the CaSR regulates cell activation through the NF-κB pathway (Zhai et al., 2017). In lymphocytes, the CaSR has been seen to promote cytokine secretion through distinct pathways, including MAPKs and NF-κB, and to induce T-cell apoptosis by interacting with the transient receptor potential canonical (TRPC) 3 and TRPC4 channels through the PLC-IP₃ pathway (Li et al., 2013; Wu et al., 2015b; Wu et al., 2015a; Zeng et al., 2016).

The CaSR is therefore a key player in immune cell activation and, as such, it seems to contribute to the pathophysiology of many inflammatory diseases, including myocardial infarction (Liu et al., 2015; Zeng et al., 2018), sepsis (Wu et al., 2015b; Wu et al., 2015a), rheumatoid arthritis (Jäger et al., 2020), and orchitis (Su et al., 2020).

In addition to its active role in regulating immune response, the CaSR also seems to be an immune target in autoimmune reactions. As for idiopathic hypoparathyroidism and acute polyendocrine syndrome, CaSR-specific autoantibodies were identified in patient serum, implying a putative involvement of a CaSR-targeted autoimmunity in the etiology of those particular disorders (Li et al., 1996; Mahtab et al., 2017; Kemp et al., 2018). Mahtab et al. (2017) found specific CD8⁺ T cells able to react with CaSR peptides in the serum of patients suffering from idiopathic hypoparathyroidism, and Habibullah et al. identified particular subsets of CaSR-autoantibodies, which were able to target the CaSR and promote its activity, thereby exacerbating parathyroid gland inactivity (Habibullah et al., 2018).

Curiously, in several case studies of cancer patients receiving treatments for immune check point inhibitors, a well-established anticancer treatment that restores immune reactivity against cancer cells, the patients manifested hypocalcemia and hypoparathyroidism, which could be ascribed to the presence of CaSR-specific autoantibodies found in the sera (Piranavan et al., 2019; Trinh et al., 2019; Dadu et al., 2020; Lupi et al., 2020). The reason of this endocrine sequalae after the treatments with immune check-points inhibitors is still under investigation and yet not understood, but merit appropriate investigation to ameliorate long-term patients’ quality of life and guarantee their survival.

Alzheimer’s disease (AD) is a neuro-dysfunction with huge social and economic impacts, especially in well-developed countries with advanced healthcare systems, where the elderly population is increasing. AD is the most recurrent form of dementia in elderly, characterized by cognitive impairment, caused by neurodegeneration and neuronal network loss (2022 Alzheimer’s disease facts and figures, 2022). The pathogenesis of AD is extremely complex and not yet completely understood, but partially ascribed to chronic neuroinflammation and the neurotoxic effects induced by the gradual deposition of interneuron plaques, formed of insoluble amyloid-β (Aβ) fibers, and by intraneuronal neurofibrillary tangles of hyperphosphorylated Tau proteins (Kumar et al., 2022). During the early phases of the disease, there is a progressive accumulation of toxic insoluble Aβ fibers due to the disruption of the metabolism of amyloid precursor protein (APP), an important factor in neuronal development (Dal Prà et al., 2019). In this context, the CaSR has been found to play a key role in the pathogenesis of AD and in modulating neuronal inflammation (Chiarini et al., 2016; Dal Prà et al., 2019). The first hint of a possible CaSR involvement in the pathogenesis of AD came from the discovery that soluble Aβ (sAβ) is able to bind the CaSR and to behave as a CaSR agonist (Ye et al., 1997; Conley et al., 2009; Dal Prà et al., 2014). Moreover, genetic CaSR polymorphisms have been seen to strongly associate with AD (Conley et al., 2009) and, in a particular animal model of AD, namely the 3xTg, the CaSR was found to be aberrantly up-regulated (Gardenal et al., 2017). sAβ-CaSR interaction seems to promote a noxious signaling in neurons, which leads to neuronal inflammation and death (Chiarini et al., 2016; Dal Prà et al., 2019). Indeed, sAβ-CaSR binding has been observed to promote the over-expression of new Aβ oligomers that progressively accumulate in neurons, causing subsequent cytotoxic effects that could be abolished through CaSR downregulation or with the administration of CaSR inhibitors (Ye et al., 1997; Conley et al., 2009; Armato et al., 2013; Bai et al., 2015; Chiarini et al., 2017; Feng et al., 2020). Moreover, sAβ-CaSR interaction has been shown to induce the synthesis of nitric oxide and vascular endothelial growth factor (VEGF)-A that concurrently participate in the AD pathogenesis (Dal Pra et al., 2005; Dal Prà et al., 2014).

Recent studies have reported a direct contribution of the CaSR in regulating the expression of pro-inflammatory cytokines in neurons such as IL-6, intercellular adhesion molecule-1 (ICAM-1), Regulated upon Activation normal T cell Expressed and presumably Secreted (RANTES) and monocyte chemotactic protein (MCP)-2 (Chiarini et al., 2020a). The CaSR was additionally found to mediate a pro-inflammatory stimulus after tissue damage, as observed in a mouse model of brain hemorrhage, where CaSR expression was up-regulated after injury, and its stimulation with Gd³⁺ increased NLRP3 and IL-1β expression (Wang et al., 2020).

Due to its direct involvement in neuroinflammation and AD dysfunction, the CaSR has been thought to behave as a danger-sensing/pattern recognition receptor in AD pathogenesis (Chiarini et al., 2020b) and, thus, it is thought to be a promising molecular target for AD treatment by using existing calcilytics (Chiarini et al., 2016; Dal Prà et al., 2019; Chiarini et al., 2020b).

Pharmacological inhibition of the CaSR has recently been proposed as a new and effective therapeutic strategy for the treatment of asthma, given the putative pro-inflammatory role that the CaSR seems to play in the lungs (Yarova et al., 2015; Corrigan, 2020; Yarova et al., 2021). The first hint of a possible involvement of the CaSR in the pathophysiology of asthma came from the observation that in inflamed lungs of asthmatics there is an accumulation of known CaSR agonists, i.e., eosinophil cationic protein, spermine, spermidine, and putrescine, that seem to directly contribute to airway hyperresponsiveness (AHR) and lung inflammation (Kurosawa et al., 1992; Coyle et al., 1993; Gibson et al., 1998; Koller et al., 1999; Homma et al., 2005; Pégorier et al., 2006; North et al., 2013). In 2010, Cortijo et al. (2010) found that nickel ions were able to induce epithelial contraction and the release of pro-inflammatory cytokines by targeting and stimulating the CaSR, while CaSR inhibition through calcilytics abolished those effects. Afterwards, the proof of a direct involvement of the CaSR in the pathophysiology of asthma came from a study by Yarova et al. (2015), who observed that CaSR was over-expressed in bronchial smooth muscle cells of asthmatics and that pharmacological inhibition of the CaSR, by administering the calcilytic NPS2143 through inhalation, could abrogate AHR and lung inflammation. Later studies also confirmed the anti-inflammatory effects of calcilytics, which were found to be able to abolish the pro-inflammatory stimuli triggered by cigarette smoke extracts (Lee et al., 2017b) and by bacterial lipopolysaccharide (LPS) (Lee et al., 2017a). Recently, a panel of calcilytics, previously developed for the treatment of osteoporosis but found to be not clinically effective on bone anabolism, were tested in asthma models and resulted to be effective in counteracting asthmatic symptoms (Yarova et al., 2021). Thanks to their capacity to inhibit both AHR and lung inflammation, and thanks to their route of administration (i.e., inhalation, which can avoid systemic undesired effects), calcilytics are thought to be promising new therapeutics for the treatment of asthma, thus constituting a novel and effective replacement for existing steroids (Corrigan, 2020).

The CaSR plays important roles in the physiology of the cardiovascular system. It is expressed and functional in cardiomyocytes, vascular smooth muscle cells (vSMCs), and vascular endothelial cells, where it regulates heart contractility, blood pressure, vessel tone (Wang et al., 2003; Schepelmann et al., 2015; Horinouchi et al., 2020), and even systemic mineral metabolism (Schepelmann et al., 2022). The CaSR is also implicated in the pathophysiology of cardiovascular diseases, such as myocardial infarction (MI), heart failure, hypertension, atherosclerosis, vascular calcification, and ischemia/reperfusion (I/R)-injury (Sundararaman and van der Vorst, 2021). Moreover, a CaSR polymorphism, A986S, has been associated with coronary artery diseases (März et al., 2007).

Cardiovascular morbidities are complex disfunctions, in which inflammation plays a major role in development and progression. Nonetheless, the CaSR seems to regulate the inflammatory response at the site of the vascular and cardiac lesions by directly acting both in tissue and in local immune cells. In a rat model of hypertension, in particular in vSMCs, the CaSR has been found to promote the release of pro-inflammatory cytokines through the NLRP3 inflammasome (Zhang et al., 2019). Leng et al. (2019) found that, in inflamed vascular endothelial cells, the CaSR promotes the release of the pro-inflammatory cytokines IL1-β and IL-18 through the activation of the NLRP3 inflammasome and the NF-κB pathway. In neonatal rat cardiomyocytes, pharmacological CaSR stimulation was found to enhance the LPS-driven pro-inflammatory stimulus, while CaSR inhibition attenuated the inflammatory response (Wang et al., 2013). Zhang et al. (2020) observed that, in a cardiac muscular cell line and in ventricular cardiomyocytes, the CaSR modulated monocyte chemotactic protein-1 (MCP-1)-driven apoptosis after I/R-injury. Conversely, a recent study from Guha et al. (2020) reported that, in inflamed aortic endothelial cells, CaSR stimulation by γ-glutamyl-valine reduced the expression of the pro-inflammatory cytokines IL-8, IL-6 and TNF-α. Nevertheless, most of the published studies outline the pro-inflammatory role of the CaSR in the cardiovascular system, as further evidenced by the fact that the CaSR has also been shown to promote cardiovascular lesions through the recruitment and activation of the immune cells (Sundararaman and van der Vorst, 2021).

Liu et al. (2015) observed that the CaSR, expressed in the macrophages, contributes to cardiac remodeling after MI via the activation of the NLRP3 inflammasome. Still under MI insult, the CaSR has been found to be up-regulated in peripheral and infiltrating neutrophils, and its pharmacological stimulation with calindol has been seen to promote neutrophil NLRP3 inflammatory response, furthermore provoking myocardial apoptosis and fibrosis (Ren et al., 2020). The CaSR has been found to mediate, via the NF-κB pathway, T lymphocyte activation and cytokine release in patients suffering from acute MI (Zeng et al., 2016) and to exacerbate cardiomyocyte lesions under myocardial ischemia and I/R-injury (Zeng et al., 2018).

In addition to its direct impact on the cardiovascular physiology and inflammation, the CaSR can putatively cause cardiovascular diseases by interfering with the metabolism of the adipose tissue and promoting adipose inflammation, which are typical hallmarks of obesity, a known risk factor for the development of cardiovascular diseases.

Among the many physiological roles that the CaSR plays, this receptor can also control lipid metabolism and adipogenesis (Bravo-Sagua et al., 2016; Mattar et al., 2020). In 2005, Cifuentes et al. (2005) found, for the first time, the CaSR to be expressed in adipose tissue. Afterwards, the CaSR was reported to regulate adipocyte differentiation and adipogenesis by promoting the expression of adipocyte regulatory transcription factors (He et al., 2012; Villarroel et al., 2013), to regulate preadipocyte proliferation through ERK1/2 activation (Rocha et al., 2015), and to inhibit lipolysis (Cifuentes and Rojas, 2008) by decreasing cAMP levels and inhibiting protein kinase A (PKA) activity (He et al., 2011). However, the CaSR has been shown to promote adipose inflammation, thereby altering lipid metabolism and possibly contributing to obesity (Villarroel et al., 2014; Bravo-Sagua et al., 2016). Adipose CaSR expression seems to be upregulated under obese-associated inflammatory stimuli (Cifuentes et al., 2010) and, on the other hand, pharmacological CaSR stimulation has been seen to promote the expression of the pro-inflammatory cytokines IL1-β, IL-6, TNF-α and the chemokine CCL2, through the NF-κB pathway (Cifuentes et al., 2012; Rocha et al., 2015) and the NLRP3 inflammasome (D’Espessailles et al., 2018).

Autophagy has also been shown to contribute to adipocyte dysfunction in obesity, and the CaSR seems to regulate this process by promoting the formation of the autophagosome (Mattar et al., 2018). The expression of the CaSR and autophagy markers were found to correlate with the percentage of body fat, thus implying a tight bond between the CaSR and autophagy in the pathophysiology of obesity (Mattar et al., 2020).

Obesity is also characterized by the infiltration of immune cells within the adipose tissue, which further contributes to adipose inflammation and lipid dysfunction, where the CaSR seems to be a key player in these processes. In THP-1 macrophages, CaSR stimulation with cinacalcet has been seen to activate the NLRP3 inflammasome and induce the expression of TNF-α and IL-1β in co-cultured preadipocytes (D’Espessailles et al., 2020). Moreover, a recent study from Thrum et al. showed that CaSR stimulation with increasing concentrations of extracellular Ca²⁺ promoted IL-1β expression, in particular in macrophages and adipocytes derived from obese patients, which were more sensitive to CaSR-induced pro-inflammatory stimulus compared to macrophages and adipocytes derived from healthy donors (Thrum et al., 2022).

Despite the numerous studies that attest a pro-inflammatory role, other recent reports have published contradicting results. Xing et al. observed that stimulating the CaSR with γ-glutamyl-valine abolished the TNF-α-induced pro-inflammatory stimulus in adipocytes (Xing et al., 2019); while Sundararaman et al. did not find any CaSR-dependent effects on visceral adipose inflammation in mice with adipose-specific CaSR knock-out (Sundararaman et al., 2021). In light of these contradictory findings, more studies are needed to clarify whether the CaSR induces inflammation in the adipose tissue and whether it does so by acting directly in the adipocytes or only by promoting immune cell infiltration and activity.

The CaSR seems to contribute to the inflammatory response in the upper digestive tract. In the epithelium of the esophagus, the CaSR seems to mediate a pro-inflammatory response through the activation of the NLRP3 inflammasome. This assertion is based on a recent observation, using in vitro and in vivo models of reflux esophagitis, where Tojapride, a natural formulation from Chinese traditional medicine, was seen to alleviate the inflammatory stimuli by interfering with the CaSR-NLRP3 signaling cascade (Yin et al., 2020). A very recent publication observed a pro-inflammatory role of the CaSR even in dental pulp cells, where it was found to mediate the expression of the pro-inflammatory markers IL-1β, IL-6, TNF-α and COX2-derived PGE₂ under LPS challenge (An et al., 2022).

The CaSR is multifunctional in the intestine, where it mediates fluid absorption, gut motility, and the secretion of digestive hormones and electrolytes (Geibel et al., 2006; Wang et al., 2011; Tang et al., 2018). According to previous literature, the CaSR seems to exert a protective function against intestinal inflammation, which was extensively illustrated in a recent review from Iamartino et al. (2018). At the time, the authors reasoned that the CaSR, by acting as a nutraceutical sensor and, thus, by sensing byproducts of digestion, could link the beneficial effects of a healthy diet rich in calcium with intestinal health. Moreover, they speculated about how the CaSR could be a possible drug target using existing calcimimetics for the treatment of intestinal disorders, such as colorectal cancer and inflammatory bowel diseases (IBDs) (Iamartino et al., 2018). These authors based their hypotheses on previous reports that observed anti-inflammatory effects of the CaSR both in vivo and in vitro. Cheng et al. reported that intestine-specific CaSR KO mice were more susceptible to dextran sulphate sodium (DSS)-induced colitis. In this study, the animals lacking intestinal CaSR presented a higher recruitment of immune cells in the bowel, higher expression of pro-inflammatory cytokines, an altered composition of intestinal microbiome, a reduced expression of tight junction markers, e.g., claudin 2, and, thus, a compromised epithelial integrity (Cheng et al., 2014). These findings were corroborated by subsequent studies where CaSR stimulation with either poly-L-lysine, glutamyl dipeptides, or l-amino acids reduced inflammation in vitro, i.e., in TNF-α challenged colorectal cancer cell lines Caco2 and HT29, and in vivo both in DSS-induced colitis mouse models (Mine and Zhang, 2015a; Mine and Zhang, 2015b; Zhang et al., 2015) and in LPS-challenged piglets (Liu et al., 2018). Recent studies further observed an anti-inflammatory effect of the CaSR, showing how CaSR stimulation with either tryptophan or spermine can enhance intestinal barrier integrity and the expression of tight junction markers, while also attenuating the pro-inflammatory stimuli driven by TNF-α, enterotoxigenic E. Coli, or LPS in porcine intestinal epithelial cells (Liu et al., 2021a; Liu et al., 2021b; Gao et al., 2021). Moreover, tryptophan-driven CaSR stimulation was seen to increase the production of endogenous defensins, hence improving host immune defense (Gao et al., 2021).

Nevertheless, new studies reported conflicting data regarding the effects of the CaSR in bowel inflammation, outlining a pro-inflammatory impact. In the attempt to assess the therapeutic applicability of the calcimimetics for the treatment of IBDs, Elajnaf et al. administered by gavage either two positive allosteric CaSR modulators, cinacalcet and a newly synthetized not absorbable calcimimetic, GSK3004744 (Sparks et al., 2017), or calcilytic NPS2143, to DSS-treated mice, which were used as a preclinical model of colitis. These authors found that pharmacological stimulation of the CaSR with cinacalcet increased the serum levels of TNF-α, IL-6, and IL-1α, implying a systemic effect of cinacalcet in enhancing inflammation, while the effects of GSK3004744, which acted locally and exclusively within the mucosa, were negligible. Surprisingly, the administration of NPS2143 reduced distress scores and immune cell infiltration in the mucosa. The authors reasoned that those effects were most likely systemic, acting on circulating immune cells, since the gut-restricted GSK3004744 did not significantly influence the inflammatory parameters (Elajnaf et al., 2019). In a subsequent study from Iamartino et al. (2020), it was observed a direct pro-inflammatory effect of the CaSR in intestinal epithelial cells. Using two colorectal cancer cell lines over-expressing the CaSR fused to the green fluorescent protein (GFP), HT29^CaSR-GFP and Caco2^CaSR-GFP cells, and comparing them with their corresponding negative controls (HT29^GFP and Caco2^GFP), they observed that only those expressing the CaSR and treated with the positive allosteric CaSR modulator, NPS R-568, had an increased expression of pro-inflammatory markers IL-8, IL-23α, IL-1α, CSF1, CCL20, COX2, and PDL1, and increased secretion of IL-8 (Iamartino et al., 2020). These findings were further confirmed by a recent study from the same research group, where they compared the CaSR-specific R-enantiomers with the CaSR-unspecific S-enantiomers derived from the allosteric CaSR modulators NPS R-568 and NPS2143. According to the authors this was done in order to exclude possible off-target effects that the allosteric CaSR modulators (the R-enantiomers) may have exerted on inflammatory markers in a CaSR-independent manner, possibly acting on other GPCRs or calcium channels. It was observed that only R-enantiomers were able to modulate intracellular calcium mobilization and IL-8 secretion, thus demonstrating a CaSR-dependence of the pro-inflammatory effects induced by the calcimimetic NPS R-568 (Schepelmann et al., 2021).

One of the possible explanations for the discrepancy of the published results could be the type of molecules used to stimulate the CaSR and the cell models employed. Despite targeting the CaSR with less-specific nutraceutical molecules, such as polyamines, dipeptides and amino acids, Elajnaf et al. (2019) were the first to test highly CaSR-specific synthetic compounds in animal models of colitis. Moreover, Iamartino et al. (2020) and Schepelmann et al. (2021) used colorectal cancer cell lines over-expressing the CaSR compared to not transduced cells (Mine and Zhang, 2015a; Mine and Zhang, 2015b; Zhang et al., 2015; Liu et al., 2018), where, in particular in the Caco2 and HT29 cell lines, the endogenous CaSR expression is reduced or even undetectable.

Therefore, due to the conflicting data, the role of the CaSR in intestinal inflammation is still unresolved and thus needs further clarification. This is important because intestinal CaSR may be linked to the gastrointestinal side effects observed in patients under prolonged treatment with cinacalcet or etelcalcetide, the newly FDA-approved calcimimetic. Pharmacovigilance studies have reported that cinacalcet and etelcalcetide are not well-tolerated after prolonged periods of administration, since patients manifest distress and discomfort, suffering from nausea, vomiting and gastrointestinal bleeding (Block et al., 2017; AMGEN Sensipar, 2022). Whether these effects are connected to a possible pro-inflammatory role of the CaSR in the intestine is still under debate and necessitates clarification, in particular in light of the possible detrimental effects that a calcimimetic-based therapy could exert in patients suffering from colitis. Moreover, clarifying whether pharmacological CaSR inhibition has beneficial effects against intestinal inflammation will open the way to new therapeutic approaches based on the use of calcilytics for the treatment of IBDs.

It is well known that the CaSR regulates mineral balance in the kidneys, but it also seems to be involved in the pathophysiology of several renal defects.

These include I/R renal injury (Weekers et al., 2015), further exacerbated by diabetic comorbidity, where the CaSR seems to enhance oxidative stress and boost the inflammatory response (Hu et al., 2018).

Tubular interstitial defects, where the CaSR, expressed in the inner medullary collecting duct cells, seems to induce tubular interstitial fibrosis by promoting collagen expression under the pro-inflammatory stimulus driven by IL1-β (Wu et al., 2019).

In the medullary thick ascending limb, the CaSR seems able to mediate sodium excretion by promoting COX-2 expression and prostaglandin production, in particular PGE₂, and it does so by inducing the expression of TNF-α, linking in this way a pro-inflammatory stimulus to natriuresis (Wang et al., 2001; Wang et al., 2002; Ferreri et al., 2012).

The CaSR has been hypothesized to provoke glomerular damage by coupling with the TRPC6 and boosting intracellular calcium influx, which has been ascribed as one of the principal culprits in the pathophysiology of membranous nephropathy (Huang et al., 2021) and in acute kidney injuries that frequently occur in septic patients (Yadav et al., 2021). However, as the authors suggested, direct evidences on these regards are missing and, thus, further studies are needed to clarify the possible implication of the CaSR in glomerular defects under inflammatory stimuli.

Finally, the CaSR has also been associated to nephrocalcinosis and nephrolithiasis, common inflammatory renal defects, which are also recurrent morbidities in ADH patients and are strongly associated with hypercalciuria (Roszko et al., 2022). Moreover, single nucleotides CaSR polymorphisms have been associated to calcium nephrolithiasis, in particular the rs6776158 (A > G) polymorphism, resident on CaSR first promoter, which is associated with decreased transcriptional activity (Vezzoli et al., 2013; Vezzoli et al., 2019). However, the underlying molecular mechanisms that link CaSR genetic variability to kidney stones are still uncovered.

Because hypercalcemia is a well-known risk factor for pancreatitis (Felderbauer et al., 2007), and given the tight bond between the CaSR and serum calcium homeostasis, it was speculated that CaSR mutations or SNPs could be linked to pancreas inflammation. However, there are conflicting results regarding this topic and thus the question is still under debate (Felderbauer et al., 2007; Murugaian et al., 2008; Stepanchick et al., 2010; Xiao et al., 2017; Ewers et al., 2021).

In the bones, the CaSR is known to promote osteogenesis and mineralization (Dvorak-Ewell et al., 2011; Chang et al., 2013), but it has also been seen to promote aberrant new bone formation in ankylosing spondylitis (AS), a chronic inflammation of the axial skeleton. The CaSR was found to be aberrantly up-regulated in osteoblasts derived from patients suffering from AS. Moreover, in several animal models of AS, CaSR inhibition attenuated AS symptoms (Li et al., 2020). Despite the pivotal calcitropic role of the bone tissue, where the CaSR is markedly expressed, reports addressing a direct function of the CaSR in bone inflammation are still missing.

Interestingly, metastatic breast cancer cells seem to exploit CaSR capability to drive cytokine secretion, in order to promote their chemotaxis and angiogenesis, as observed in the highly invasive MDA-MB-231 breast cancer cell line stimulated with CaSR allosteric modulator NPS-R568 (Hernández-Bedolla et al., 2015; Hernández-Bedolla et al., 2016). Furthermore, in MDA-MB-231 and in the MCF-7 breast cancer cell lines, CaSR stimulation was found to enhance the expression of Rab27B, a Rab GTPase that is involved in endosomal trafficking (Zhen and Stenmark, 2015), promoting in this way the secretion of pro-inflammatory cytokines and chemokines such as IL-6, IL-1β, IL-8, IP-10 and RANTES (Zavala-Barrera et al., 2021).